The Milwaukee Journal-Sentinel has started another interesting health care series – this one called “Insufficienct Evidence.” First entry: “Health care tries to figure out what works best,” by Guy Boulton.
Borrowing a line from “When Harry Meets Sally,” newspapers across the country should say, “I’ll have whatever she’s having” if they look and see the terrific work that the Milwaukee paper is doing on health care topics. John Fauber’s “Side Effects” series on conflicts of interest in health care has been going on for more than a year.
Opinions on other issues in news, journals, PR, advertising, marketing
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments (4)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Greg Pawelski
May 3, 2010 at 1:23 pmI think one good recent example of comparative effectiveness research in cancer medicine was a Duke University cost savings study on the impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. They sought to estimate mean costs of chemotherapy treatment with or without use of a chemoresponse assay.
They estimated mean costs for 3 groups: (1) assay assisted: 75 women who received oncologist’s choice of chemotherapy following chemoresponse testing (65% adherence to test results), (2) assay adherent: modeled group assuming 100% adherence to assay results, and (3) empiric: modeled from market share data on most frequently utilized chemotherapy regimens. Cost estimates were based on commercial claims database reimbursements.
The most common chemotherapy regimens used were topotecan, doxorubicin, and carboplatin/paclitaxel. Mean chemotherapy costs for 6 cycles were $48,758 (empiric), $33,187 (assay assisted), and $23,986 (assay adherent). The cost savings related to the assay were associated with a shift from higher- to lower-cost chemotherapy regimens and lower use of supportive drugs such as hematopoiesis-stimulating agents.
Conclusion of the study was that assay-assisted chemotherapy for recurrent ovarian cancer may result in reduced costs compared to empiric therapy. What most medical oncologists do now (PMID: 20417480).
What complex treatment regimens work best for which patients? You’d think that the evidence needed to answer the question for individual cancer patients doesn’t exist. Sometimes the most effective treatment options cost less. Again, you’d think that any savings would be a decade or more away. You’d think that we don’t have enough evidence on how to use the drugs that we already have.
The answer? It’s right there in front of us. Perhaps thinking-outside-the-box would work wonders.
Brenda
May 5, 2010 at 2:23 amI consider this blog – and the website – to be a gift to humanity.
One thing I’d like to point out, as a journalist who has reported on health, is the important educational role that experts can play when they are interviewed. Many years ago, when I was just starting out, a doctor took the time to emphasize the rules of reporting on studies as they related to his research. It only took a few minutes, but it made a great impact on me. It showed me how much he cared about the accuracy of the final product and it put his main idea into context in an important way.
Thanks again! I’ll be visiting the blog and site frequently.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like